Basel Medical Group Ltd
BMGL
$2.02
-$0.17-7.76%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.89M | 1.91M | 1.83M | 1.85M | 1.89M |
| Total Other Revenue | 2.50K | 2.50K | 6.60K | 6.70K | 800.00 |
| Total Revenue | 1.89M | 1.91M | 1.84M | 1.86M | 1.89M |
| Cost of Revenue | 1.46M | 1.48M | 1.22M | 1.23M | 961.10K |
| Gross Profit | 429.10K | 433.80K | 623.10K | 629.20K | 925.50K |
| SG&A Expenses | 45.00K | 45.50K | 258.00K | 260.50K | 1.20K |
| Depreciation & Amortization | 131.80K | 133.30K | 97.40K | 98.30K | 98.30K |
| Other Operating Expenses | 466.10K | 471.20K | 169.90K | 171.50K | 131.20K |
| Total Operating Expenses | 2.10M | 2.13M | 1.74M | 1.76M | 1.19M |
| Operating Income | -213.80K | -216.20K | 97.90K | 98.80K | 694.90K |
| Income Before Tax | -118.80K | -120.10K | 172.30K | 174.00K | 718.20K |
| Income Tax Expenses | 100.00 | 100.00 | -103.30K | -104.30K | 226.60K |
| Earnings from Continuing Operations | -118.90K | -120.20K | 275.70K | 278.40K | 491.60K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -118.90K | -120.20K | 275.70K | 278.40K | 491.60K |
| EBIT | -213.80K | -216.20K | 97.90K | 98.80K | 694.90K |
| EBITDA | -206.20K | -208.40K | 103.10K | 104.20K | 700.70K |
| EPS Basic | -0.01 | -0.01 | 0.02 | 0.02 | 0.03 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.01 | 0.01 | 0.03 |
| EPS Diluted | -0.01 | -0.01 | 0.02 | 0.02 | 0.03 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.01 | 0.01 | 0.03 |
| Average Basic Shares Outstanding | 16.25M | 16.25M | 16.25M | 16.25M | 16.25M |
| Average Diluted Shares Outstanding | 16.25M | 16.25M | 16.25M | 16.25M | 16.25M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |